Puma Biotechnology, (NYSE:PBYI) is a $3.2 billion market cap company initially focused on developing tyrosine kinase inhibitor neratinib (PB272) for HER2 positive breast cancer. The company has conducted 11 clinical trials for its lead candidate, with over 2,000 patients contributing to a favorable risk-benefit profile, per inflection point clinical trial readouts over the past quarter. Oncologic Drugs Advisory Committee (ODAC) at FDA recently voted for approval of neratinib in HER2 positive extended adjuvant treatment of early stage breast cancer in May 2017. ODAC vote is not binding but carries strong weight in the decision-making process. Given FDA director Gottlieb's new aggressive policies regarding the slow and outdated drug approval process at FDA, this was seen by the market as a "sure thing". The company is advancing neratinib in discussions with EMA for European markets, with validation in August 2016. Other investigations include neratinib in combinatory therapy for metastatic breast cancer and in solid tumors as well.
Neratinib blocks signal cascades of epidermal growth factor receptors or EGFRs, specifically: HER1, HER2, HER3, and HER4. A number of studies are showing nice anti-tumor efficacy. Taken together with ODAC favor, Phase 3 result emphasis for neratinib which met primary endpoints appears to have led to the robust response in the market for high probability of FDA approval. Two-year disease-free survival showed a 2.4% improvement for neratinib versus placebo in ITT population. Five-year disease-free survival showed a 2.5% improvement. In HR+ patients, neratinib adjuvant therapy showed a two-year disease-free survival rate of 95.4% compared to 91.2% in placebo. Five-year disease-free survival conferred a 4.8% benefit. Two-year HR patients' disease-free survival showed a meaningful advantage, but five-year data was not statistically significant.
The company recently presented data June 3 at ASCO 2017 summarizing positive results of its Phase 2 trial in HER2-positive metastatic breast cancer that has metastasized to the brain. Nearly half of the patients in a neratinib plus chemotherapy cohort achieved a central nervous system (CNS) objective response with overall survival data remaining immature at 13.5 months (and counting). CNS progressions remain a huge comorbidity factor in patients with brain metastases. With the ability to cross the blood-brain barrier, and with diarrhea being the number one adverse event, PBYI is well-positioned to advance in this space with neratinib. Studies examining antidiarrheal prophylaxis (Loperamide) to reduce diarrhea severity during neratinib treatment have proven effective. Phase 3 data showed grade 3 diarrhea decreased from ~40% to ~31% with loperamide, to ~23% with loperamide and budesonide, and to 11.5% with loperamide and colestipol. Safety studies examining children and young adults with cancer are also ongoing.
Multiple studies are generating impressive cancer therapy data for neratinib, including clinical data presented at AACR on neratinib in the treatment of patients who have solid tumors with activating HER2 or HER3 mutations. Additional data was also presented on the combination of T-DM1 and neratinib in patients with HER2 positive metastatic breast cancer (MBC) that has previously been treated with pertuzumab and trastuzumab. The company has done extensive analysis of breast cancer NSABP FB-7 biomarker during neratinib treatment with a variety of immuno and chemotherapy regimens to qualify its objective tumor response. Mechanistically, phosphoHER2 levels and truncated HER2 mutants (p95HER2) demonstrated statistically significant higher levels in patients who achieved a pCR with neratinib than those treated with trastuzumab or trastuzumab plus neratinib who did not. Moreover, dual pathway suppression (HR/ER+ and EGFR/HER2+) has been seen only in neratinib and not in Herceptin and Tykerb (Novartis (NYSE:NVS)).
The company has listed other potential tissue types to expand its label for neratinib, including non-small cell lung cancer, colorectal cancer, and solid tumors (any HER2-associated tumors). Roche (OTCQX:RHHBY) annual sales for Herceptin (trastuzumab) approach $5 billion. In contrast, Tykerb has not fared as well due to its unfavorable toxicity profile, with sales in the hundreds of millions. The HER2 positive breast cancer market is estimated to be about $13 billion by 2023. Given this massive market and plenty of room to expand label into other high dollar indications, Puma may still have quite a bit of upside and is generally de-risked. It certainly becomes very attractive on any stock price pullbacks.
Puma reported at end of 1Q 2017 cash and cash equivalents of $105.1 million and marketable securities of $88.9 million, with a 1Q net loss of $72 million. Cash runway is expected to last through mid-2018, with a burn rate of approximately $35 million per quarter. If the company is forced to raise funds, it should be able to do so at a good market value, given the advanced stage of its drug development. Strong Bio recommends a watch list spot for the stock and manageable delays or setbacks as a potential buying opportunity. Moreover, it may be a takeover candidate and could undergo some downward volatility in the standard process of stop-loss triggering. Such swoons will probably not last long as market support should be strong. With market cap of $3 billion and potential market quite a bit larger, there is plenty of room for value position here if sales meet expectations.
Risks for the company to investors are primarily centered around its one-trick pony pipeline. But when the trick is good enough, it's going to bring bank. Its advantage in efficacy will certainly gain a reasonable stake in the market for those that can tolerate the adverse events. In fact, the adverse event of diarrhea is somewhat severe, but luckily, most of that risk was mediated with appropriate prophylaxis regimen. It perhaps would have contraindications for those with extreme inflammatory bowel or related disorders. FDA-related large scale manufacturing risks and regulatory hurdles could prove to add delays and pitfalls to Puma's terrain, and since this is the only revenue-maker in its pipeline, a lot hinges on its expeditious advancement. However, given the aggressive stance at FDA to get life-saving therapies available to patients, most regulatory risks are ameliorated. Partnership decisions will be important inflection points moving forward.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.
Here is the original post:
Puma Stalks Up - Puma Biotechnology, Inc. (NYSE:PBYI) | Seeking ... - Seeking Alpha
- Plant biotechnology 3 - Video - January 1st, 2014 [January 1st, 2014]
- Press Release - April 9th, 2014 [April 9th, 2014]
- Biotech Suffers Record Exit at Largest ETF Signaling Turn - April 9th, 2014 [April 9th, 2014]
- Biotechnology World Congress 2014 | Biotechnology ... - April 9th, 2014 [April 9th, 2014]
- What is Biotechnology? - Access Excellence @ the National ... - April 9th, 2014 [April 9th, 2014]
- What is Biotechnology? - BIO | Healing, Fueling and ... - April 9th, 2014 [April 9th, 2014]
- Biotechnology - Wikipedia, the free encyclopedia - April 9th, 2014 [April 9th, 2014]
- IUBP Day5 2 Emerging Opportunities in Biotechnology - Video - April 9th, 2014 [April 9th, 2014]
- B.Tech(Biotechnology), BATCH 2008/09, SVPUAT MEERUT.............. FRIENDS FOREVER...... - Video - April 9th, 2014 [April 9th, 2014]
- Bharat Book Presents : Global Pharmaceutical & Biotechnology Outlook 2014 Mature Biotech - Video - April 9th, 2014 [April 9th, 2014]
- Bharat Book Presents : Global Pharmaceutical & Biotechnology Outlook 2014 Japan Pharma - Video - April 9th, 2014 [April 9th, 2014]
- Bharat Book Presents : Global Pharmaceutical & Biotechnology Outlook 2014 India Pharma - Video - April 9th, 2014 [April 9th, 2014]
- Bharat Book Presents : Global Pharmaceutical & Biotechnology Outlook 2014 Rising Stars - Video - April 10th, 2014 [April 10th, 2014]
- Nasdaq Rout Curbs 2000-Like Boom in Israeli Share Sales - April 15th, 2014 [April 15th, 2014]
- A Glimpse into Biotechnology - Video - April 15th, 2014 [April 15th, 2014]
- Biotechnology: gel electrophoresis, PCR - Video - April 15th, 2014 [April 15th, 2014]
- Plandai Biotechnology, Inc. Qualifies for Grant From South African Department of Trade - Video - April 16th, 2014 [April 16th, 2014]
- Biotechnology Program - University of California, Davis - April 17th, 2014 [April 17th, 2014]
- Biotechnology in Action (Arizona) - Video - April 17th, 2014 [April 17th, 2014]
- France protests new EU approved genetically modified corn ScienceDaily - Video - April 17th, 2014 [April 17th, 2014]
- Drug manufacture and Biotechnology '14 - SCOPS - final phase ( Auditing ) - Video - April 19th, 2014 [April 19th, 2014]
- Mucosis Partners With Chinese Firm Changchun BCHT Biotechnology - April 22nd, 2014 [April 22nd, 2014]
- Biotechnology-2014: Meeting the Needs of a Changing World - April 22nd, 2014 [April 22nd, 2014]
- New patenting guidelines are needed for biotechnology - April 22nd, 2014 [April 22nd, 2014]
- Biotechnology is so cool - Video - April 22nd, 2014 [April 22nd, 2014]
- Bharat Book Presents : Biotechnology Equipment Markets in China - Video - April 22nd, 2014 [April 22nd, 2014]
- New patenting guidelines needed for biotechnology, experts argue - April 24th, 2014 [April 24th, 2014]
- biotechnology videos - Video - April 24th, 2014 [April 24th, 2014]
- Kristi Snell, VP Research and Biotechnology for Metabolix, Inc. - Video - April 24th, 2014 [April 24th, 2014]
- 4th Annual International Conference: Advances in Biotechnology 2014 - Video - April 24th, 2014 [April 24th, 2014]
- Edmonds School District Biotechnology - Video - April 25th, 2014 [April 25th, 2014]
- World congress on Biotechnology - Video - April 25th, 2014 [April 25th, 2014]
- Bahir Dar university biotechnology dr tESFAYE - Video - April 25th, 2014 [April 25th, 2014]
- Algenist Skincare: Biotechnology from San Francisco - Video - April 27th, 2014 [April 27th, 2014]
- nitj biotechnology farewell batch2010-14 - Video - April 28th, 2014 [April 28th, 2014]
- Life Sciences & Biotechnology - Video - April 28th, 2014 [April 28th, 2014]
- Bolder Biotechnology Current Therapeutic Market Developmental Pipeline - Video - April 28th, 2014 [April 28th, 2014]
- Academic and Research Institutions to Play Key Role in 2014 BIO International Convention - April 29th, 2014 [April 29th, 2014]
- 19 Biotechnology - Video - April 29th, 2014 [April 29th, 2014]
- BIOTECHNOLOGY - Video - April 29th, 2014 [April 29th, 2014]
- Program Spotlight: Biotechnology - Video - April 30th, 2014 [April 30th, 2014]
- Biotechnology at Gaston College - Video - April 30th, 2014 [April 30th, 2014]
- Biotechnology - Gene Cloning - Video - April 30th, 2014 [April 30th, 2014]
- Amyris helps launch Brazilian Industrial Biotechnology Association (ABBI) - Video - May 2nd, 2014 [May 2nd, 2014]
- Julius Mugwagwa - Agro-biotechnology and Food Security - Video - May 2nd, 2014 [May 2nd, 2014]
- VIRUN's CEO, Philip Bromley, lecture - Cal Poly Pomona; Biotechnology - Video - May 2nd, 2014 [May 2nd, 2014]
- Biotechnology - gel electrophoresis - Video - May 2nd, 2014 [May 2nd, 2014]
- Plant Biotechnology Information Fair at Penn State 4/18/14 - Video - May 2nd, 2014 [May 2nd, 2014]
- Biotechnology ADHK - Video - May 2nd, 2014 [May 2nd, 2014]
- General Biology 2 - 38 Angiosperm Reproduction and Biotechnology - Flashcards - Video - May 2nd, 2014 [May 2nd, 2014]
- Impact of Biotechnology on Current Life - Video - May 3rd, 2014 [May 3rd, 2014]
- DGAP-Adhoc: Cytos Biotechnology Ltd to wind down Key Operational Activities - May 5th, 2014 [May 5th, 2014]
- Process - Genetic Engineering and Biotechnology - Video - May 6th, 2014 [May 6th, 2014]
- SAT105 Unit 3 Part 2 Biotechnology - Video - May 6th, 2014 [May 6th, 2014]
- highlights of industrial biotechnology - Video - May 6th, 2014 [May 6th, 2014]
- polymer & environmental biotechnology @ acib - Video - May 8th, 2014 [May 8th, 2014]
- SAT105 Unit 3 Part 1 Biotechnology - Video - May 8th, 2014 [May 8th, 2014]
- Talk of the Trade: Biotechnology & Health Sciences - Video - May 9th, 2014 [May 9th, 2014]
- Congratulations to the 2014 Biotechnology Graduates of Athens Technical College! - Video - May 9th, 2014 [May 9th, 2014]
- Plandai Biotechnology (PLPL) - Getting the Most Out of Nature - Video - May 10th, 2014 [May 10th, 2014]
- Stages Of Beans Growth- HU biotechnology - Video - May 11th, 2014 [May 11th, 2014]
- Revisiting the biotechnology stocks - Video - May 11th, 2014 [May 11th, 2014]
- Molecular Biotechnology - Master's Programme - Video - May 11th, 2014 [May 11th, 2014]
- Kevin Ahern's BB 350 (Biotechnology) 2014 - #22 - Video - May 12th, 2014 [May 12th, 2014]
- 5/5, Session 1 - Small biotechnology/Venture capital - Video - May 12th, 2014 [May 12th, 2014]
- Executive Interview - International Biotechnology Trust - Video - May 12th, 2014 [May 12th, 2014]
- Biotechnology Salaries | Salary.com - May 14th, 2014 [May 14th, 2014]
- Biotechnology | University of Wrocaw - Video - May 14th, 2014 [May 14th, 2014]
- JVS Bridges to College - Biotechnology Pathway Program - Video - May 16th, 2014 [May 16th, 2014]
- Biotechnology Paperslide Review by Khalizarek+Brian - Video - May 16th, 2014 [May 16th, 2014]
- Perceptions on the Future of Biotechnology by Robert Paarlberg (USA) - Video - May 16th, 2014 [May 16th, 2014]
- Plant Biotechnology - Video - May 16th, 2014 [May 16th, 2014]
- Playing with Biotechnology at the Age of 20: Kinshuk Mitra at TEDxOhioStateUniversity - Video - May 16th, 2014 [May 16th, 2014]
- biotechnology movie - Video - May 19th, 2014 [May 19th, 2014]
- New report details biotechnology's use in crops - May 20th, 2014 [May 20th, 2014]
- Biotechnology Stock Wins - Video - May 20th, 2014 [May 20th, 2014]
- Plant product of biotechnology - Video - May 21st, 2014 [May 21st, 2014]
- How Biotechnology Cure Diabetes - Video - May 22nd, 2014 [May 22nd, 2014]
- Exploring Laser-Material Interaction for Engineering, Biotechnology, and Medicine #DigInfo - Video - May 22nd, 2014 [May 22nd, 2014]
- Computers, Biotechnology, and Mass Communication - Video - May 22nd, 2014 [May 22nd, 2014]